Q-VD-Oph

Catalog No.S7311 Batch:S731103

Print

Technical Data

Formula
C26H25F2N3O6
Molecular Weight 513.49 CAS No. 1135695-98-5
Solubility (25°C)* In vitro DMSO 100 mg/mL (194.74 mM)
Ethanol 100 mg/mL (194.74 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Q-VD-Oph (Quinoline-Val-Asp-Difluorophenoxymethylketone) is a potent pan-caspase inhibitor with IC50 ranged from 25 to 400 nM for caspases 1,3,8, and 9. Q-VD-OPh can inhibits HIV infection.
Targets
Caspase-1 [1] Caspase-3 [1] Caspase-8 [1] Caspase-9 [1]
25 nM-400 nM 25 nM-400 nM 25 nM-400 nM 25 nM-400 nM
In vitro Q-VD-OPh （5-100 μM） potently inhibits Actinomycin D-induced DNA laddering and subsequent apoptosis with minimal toxicity in WEHI 231 cells. Q-VD-OPh prevents caspase mediated cleavage of PARP and activation of the major initiator and effector caspases. [2] Q-VD-OPh protects cardiac myocytes from virus-induced apoptosis in vitro. [4]
In vivo Q-VD-OPh inhibits caspase-1 activity, IL-18 protein expression, and neutrophil infiltration during ischemic ARF in mice. [3] In vivo, caspase inhibition by Q-VD-OPh provides protection from virus-induced myocardial injury, with a significant reduction in caspase-3 activity. [4] In TgCRND8 mice, Q-VD-OPh inhibits caspase-7 activation and limits the pathological changes associated with tau, including caspase cleavage. [5]

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    WEHI-231 cells

  • Concentrations

    ~1000 μM

  • Incubation Time

    4 hours

  • Method

    Caspase inhibitors are added at the indicated concentrations 30 minutes prior to the addition of apoptotic stimuli. Viability and cell number are determined by trypan blue exclusion from three random fields of greater than 200 cells/field. All experiments are performed a minimum of three times.
Animal Study:[3]
  • Animal Models

    C57BL/6 mice

  • Dosages

    ~120 mg/kg

  • Administration

    Intraperitoneal administration

Customer Product Validation

Data from [Data independently produced by , , Mol Nutr Food Res, 2017, 61(12)]

Data from [Data independently produced by , , Neurochem Res, 2018, 43(6):1200-1209]

Selleck's Q-VD-Oph has been cited by 79 publications

Mitophagy curtails cytosolic mtDNA-dependent activation of cGAS/STING inflammation during aging [ Nat Commun, 2024, 15(1):830] PubMed: 38280852
Neuronal autosis is Na+/K+-ATPase alpha 3-dependent and involved in hypoxic-ischemic neuronal death [ Cell Death Dis, 2024, 15(5):363] PubMed: 38796484
Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2 [ Cell Death Discov, 2024, 10(1):125] PubMed: 38461295
Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death [ Cells, 2024, 13(5)388] PubMed: 38474352
Deregulation of lactate permeability using a small-molecule transporter (Lactrans-1) disturbs intracellular pH and triggers cancer cell death [ Biochem Pharmacol, 2024, 229:116469] PubMed: 39117009
The clarithromycin-binding proteins NIPSNAP1 and 2 regulate cytokine production through mitochondrial quality control [ Sci Rep, 2024, 14(1):2354] PubMed: 38287119
Extracellular vesicles promote silica nanoparticle aggregation that inhibits silica-induced cytotoxicity [ Arch Biochem Biophys, 2024, 755:109964] PubMed: 38527699
Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo [ BMC Cancer, 2024, 24(1):1350] PubMed: 39497108
Treatment with siRNAs is commonly associated with GPX4 up-regulation and target knockdown-independent sensitization to ferroptosis [ Sci Adv, 2024, 10(11):eadk7329] PubMed: 38489367
Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs) [ Research Square, 2024, 10.21203/rs.3.rs-3857577/v1] PubMed: none

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.